{"nctId":"NCT00300482","briefTitle":"Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood","startDateStruct":{"date":"2006-03"},"conditions":["Dyslipidemia","Coronary Heart Disease","Mixed Dyslipidemia"],"count":1445,"armGroups":[{"label":"A","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ABT-335","Drug: Rosuvastatin Calcium"]},{"label":"B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ABT-335","Drug: Rosuvastatin Calcium"]},{"label":"C","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: ABT-335","Drug: Placebo"]},{"label":"D","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Rosuvastatin Calcium","Drug: Placebo"]},{"label":"E","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Rosuvastatin Calcium","Drug: Placebo"]},{"label":"F","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Rosuvastatin Calcium","Drug: Placebo"]}],"interventions":[{"name":"ABT-335","otherNames":[]},{"name":"Rosuvastatin Calcium","otherNames":["Rosuvastatin"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with mixed dyslipidemia\n\nExclusion Criteria:\n\n* Subjects with unstable medical conditions or medical conditions considered inappropriate in a clinical trial.\n* Patients who are taking certain medications or unstable dose of specific medications.\n* Women who are pregnant or plan on becoming pregnant or women who are lactating.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Percent Change in Triglycerides From Baseline to Final Visit","description":"\\[(Week 12 triglycerides minus baseline triglycerides)/baseline triglycerides\\] x 100","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-47.1","spread":"1.81"},{"groupId":"OG001","value":"-42.9","spread":"1.82"},{"groupId":"OG002","value":"-32.6","spread":"1.84"},{"groupId":"OG003","value":"-24.4","spread":"1.81"},{"groupId":"OG004","value":"-25.6","spread":"1.80"},{"groupId":"OG005","value":"-32.1","spread":"2.48"}]}]}]},{"type":"PRIMARY","title":"Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit","description":"\\[(Week 12 HDL-C minus baseline HDL-C)/baseline HDL-C\\] x 100","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.3","spread":"1.36"},{"groupId":"OG001","value":"19.0","spread":"1.35"},{"groupId":"OG002","value":"15.0","spread":"1.37"},{"groupId":"OG003","value":"8.5","spread":"1.32"},{"groupId":"OG004","value":"10.3","spread":"1.32"},{"groupId":"OG005","value":"9.3","spread":"1.85"}]}]}]},{"type":"PRIMARY","title":"Mean Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Final Visit","description":"\\[(Week 12 LDL-C minus baseline LDL-C)/baseline LDL-C\\] x 100","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.2","spread":"1.21"},{"groupId":"OG001","value":"-38.8","spread":"1.21"},{"groupId":"OG002","value":"-6.5","spread":"1.22"},{"groupId":"OG003","value":"-38.0","spread":"1.18"},{"groupId":"OG004","value":"-45.0","spread":"1.19"},{"groupId":"OG005","value":"-50.6","spread":"1.64"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Non-low-density Lipoprotein Cholesterol (Non-HDL-C)From Baseline to Final Visit","description":"\\[(Week 12 non-HDL-C minus baseline non-HDL-C)/baseline non-HDL-C\\] x 100","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.7","spread":"1.05"},{"groupId":"OG001","value":"-45.3","spread":"1.04"},{"groupId":"OG002","value":"-18.5","spread":"1.06"},{"groupId":"OG003","value":"-39.8","spread":"1.02"},{"groupId":"OG004","value":"-45.8","spread":"1.02"},{"groupId":"OG005","value":"-51.5","spread":"1.43"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Very Low-density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit","description":"\\[(Week 12 VLDL-C minus baseline VLDL-C)/baseline VLDL-C\\] x 100","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-55.8","spread":"3.08"},{"groupId":"OG001","value":"-50.6","spread":"3.10"},{"groupId":"OG002","value":"-31.9","spread":"3.13"},{"groupId":"OG003","value":"-41.0","spread":"3.07"},{"groupId":"OG004","value":"-42.1","spread":"3.07"},{"groupId":"OG005","value":"-49.1","spread":"4.17"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Total Cholesterol From Baseline to Final Visit","description":"\\[(Week 12 total cholesterol minus baseline total cholesterol)/baseline total cholesterol\\] x 100","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.4","spread":"0.82"},{"groupId":"OG001","value":"-35.7","spread":"0.83"},{"groupId":"OG002","value":"-13.5","spread":"0.84"},{"groupId":"OG003","value":"-32.5","spread":"0.82"},{"groupId":"OG004","value":"-37.3","spread":"0.82"},{"groupId":"OG005","value":"-42.7","spread":"1.13"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Lipoprotein Apo B (Apo B) From Baseline to Final Visit","description":"\\[(Week 12 Apo B minus baseline Apo B)/baseline Apo B\\] x 100","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.2","spread":"1.04"},{"groupId":"OG001","value":"-39.2","spread":"1.05"},{"groupId":"OG002","value":"-16.2","spread":"1.06"},{"groupId":"OG003","value":"-34.1","spread":"1.04"},{"groupId":"OG004","value":"-39.6","spread":"1.03"},{"groupId":"OG005","value":"-45.0","spread":"1.45"}]}]}]},{"type":"SECONDARY","title":"Median Percent Change in High-sensitivity C-reactive Protein (hsCRP) From Baseline to Final Visit","description":"\\[(Week 12 hsCRP minus baseline hsCRP)/baseline hsCRP\\] x 100","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.8","spread":"16.87"},{"groupId":"OG001","value":"-40.8","spread":"17.01"},{"groupId":"OG002","value":"-12.1","spread":"17.20"},{"groupId":"OG003","value":"-22.9","spread":"16.92"},{"groupId":"OG004","value":"-29.9","spread":"16.78"},{"groupId":"OG005","value":"-33.1","spread":"23.31"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10},"commonTop":["Headache","Back pain","Nausea","Arthralgia","Myalgia"]}}}